Trial Profile
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs MVX ONCO 1 (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Therapeutic Use
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Primary endpoint (Overall Survival at 26 weeks (OS)) has been met, according to Results presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Enrollment was closed early as primary endpoint was met ahead of schedule. An unplanned interim review of the first 10 pts revealed 7 had met the 26 weeks OS endpoint, according to Results presented at the 48th European Society for Medical Oncology Congress.